ArticleFrontiers in oncology2022

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis.

Taojun Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.